Milrinone

Milrinone is a medicine given into a vein. A US label for milrinone lactate injection lists it for short-term treatment of patients with acute decompensated heart failure. The label describes it as a positive inotrope, a medicine that strengthens the heartbeat, and a vasodilator, which widens blood vessels. The label says patients receiving it "should be observed closely with appropriate electrocardiographic equipment" and that treatment for "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours."

Also called Milrinone lactate

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 52769; UNII 9K8XR81MO8 is the UNII of the salt, milrinone lactate, that the label gives, so it is a broad match; MeSH descriptor D020105 (Milrinone). US drug-label class: Phosphodiesterase 3 Inhibitor (established pharmacologic class, RxClass). The MeSH scope note says it inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. The label read is the Hikma Pharmaceuticals USA label for milrinone lactate (vial and premixed dextrose forms), application ANDA077966, effective 2025-05-08 in openFDA; openFDA lists many other milrinone labels, which were not read. This page records the label indication and the class only: no trial result and no dose is given. The parent class page (inotropes and vasopressors) is not written yet, so the page has no parent link.

Trials at a glance

The figures count the 2 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
2
Phase 3 or 4
2
Recruiting
1
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingCompletedAll statuses
Phase 4112
All phases112

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

About this drug

Level
Substance
Mechanism
The MeSH scope note says milrinone inhibits cAMP phosphodiesterase type 3 activity in heart muscle and in the smooth muscle of blood vessels. The label calls it a positive inotrope and vasodilator.

Classification codes

  • UNII 9K8XR81MO8 Milrinone lactate

Claims and evidence

Context Patients for whom the US milrinone lactate injection label lists short-term intravenous treatment: acute decompensated heart failure

Recipient
Recipient not specified
Population
Patients with acute decompensated heart failure, as the indications section describes them; the sentence does not name an age group.
Care setting
Intravenous medicine used with close observation and electrocardiographic equipment, as the indications section describes
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the indication sentence
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients with acute decompensated heart failure
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of milrinone lactate injection (Hikma Pharmaceuticals, abbreviated application ANDA077966; version dated 8 May 2025 in openFDA) lists the medicine for short-term intravenous treatment of patients with acute decompensated heart failure. The same section says that patients receiving milrinone "should be observed closely with appropriate electrocardiographic equipment" and that the facility for immediate treatment of "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours." The label describes the medicine as a positive inotrope and vasodilator with little chronotropic activity.

    Applies to Recipient not specified Patients for whom the US milrinone lactate injection label lists short-term intravenous treatment: acute decompensated heart failure

    Certainty method
    Not assessed
    Limitations
    This claim records what one generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses, interactions and adverse reactions were not recorded. The label covers both the vial and the premixed dextrose product. openFDA says its data are unvalidated and not to be relied on for decisions about medical care. openFDA lists many other milrinone labels from other makers, which were not read.
    Last checked
    2026-11-08
    Next evidence check due
    Not scheduled
    Sources and citations (8)
    1. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].effective_time
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].openfda.brand_name[0]
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].indications_and_usage[0], 1 sentence 1
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].indications_and_usage[0], 1 sentence 2
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    6. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].indications_and_usage[0], 1 sentence 3
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    7. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].indications_and_usage[0], 1 sentence 5
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    8. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].clinical_pharmacology[0], 1
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

While breastfeeding 1

Claims whose context names breastfeeding, lactation or human milk.

  • Description Evidence stage not applicable Certainty not assessed

    The US label of milrinone lactate injection (Hikma Pharmaceuticals, abbreviated application ANDA077966; version dated 8 May 2025 in openFDA) lists the medicine for short-term intravenous treatment of patients with acute decompensated heart failure. The same section says that patients receiving milrinone "should be observed closely with appropriate electrocardiographic equipment" and that the facility for immediate treatment of "potential cardiac events, which may include life threatening ventricular arrhythmias, must be available." It also says "There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours." The label describes the medicine as a positive inotrope and vasodilator with little chronotropic activity.

    Applies to Recipient not specified Patients for whom the US milrinone lactate injection label lists short-term intravenous treatment: acute decompensated heart failure

    Population, setting and follow-up
    • Patients with acute decompensated heart failure, as the indications section describes them; the sentence does not name an age group.
    • Intravenous medicine used with close observation and electrocardiographic equipment, as the indications section describes
    • United States (label of the US Food and Drug Administration)
    • Not stated in the indication sentence
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records what one generic label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications section and the first sentence of the pharmacology section were read; contraindications, warnings, doses, interactions and adverse reactions were not recorded. The label covers both the vial and the premixed dextrose product. openFDA says its data are unvalidated and not to be relied on for decisions about medical care. openFDA lists many other milrinone labels from other makers, which were not read.
    Last checked
    2026-11-08
    Next evidence check due
    Not scheduled
    Sources and citations (8)
    1. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].effective_time
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].openfda.brand_name[0]
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].indications_and_usage[0], 1 sentence 1
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].indications_and_usage[0], 1 sentence 2
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    6. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].indications_and_usage[0], 1 sentence 3
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    7. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].indications_and_usage[0], 1 sentence 5
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.
    8. Supports openFDA drug label record: Milrinone Lactate (Hikma, ANDA077966)

      Label · U.S. Food and Drug Administration (openFDA drug label endpoint) · Edition openFDA drug label record, label effective 20250508, dataset last updated 2026-11-06. · SPL set id: 88f78780-399f-4780-be19-205739db1682

      Locator
      results[0].clinical_pharmacology[0], 1
      How it applies
      Quoted at this locator.
      Retrieved
      Source effective date
      2025-05-08
      Source state
      Current
      Version fingerprint
      852c38e8f63fbe1a379e8a263ba3d7f27b310b0a16f014d7f2394b6ae1974a4d
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication (https://open.fda.gov/terms/ and https://open.fda.gov/license/). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

PRIMACOR

No label from the application holder was found in the openFDA label dataset for application NDA019436. This page does not show another labeler's label in its place.

PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

No label from the application holder was found in the openFDA label dataset for application NDA020343. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA019436 PRIMACOR
  2. Approval NDA020343 PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 2

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA019436

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA020343

Registry trials 2

Record details

Record id
cardio:milrinone
Content hash
88d6d1b68f556082ab245dfcc223ff5470d15f20218759cf42343f51c7078763